Stay updated on Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial page now displays the completed study record for nivolumab, cabiralizumab, and gemcitabine in Stage IV pancreatic cancer, including study design, participant criteria, outcome measures, and a protocol document.SummaryDifference51%

- Check21 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide NIH notice was added announcing a terminology transition from “Artificial Intelligence (AI)” to “Super Intelligence (SI)” and linking to updates and FAQs.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision indicator updates from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check62 days agoChange DetectedAccess to the study page now shows a 403 Forbidden error, replacing the study content with an access-denied screen. The page content includes explicit 403 messaging and related HTML structure indicating forbidden access.SummaryDifference18%

Stay in the know with updates to Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.